Related Experiment Video
Updated: Aug 15, 2026

Heterotypic Three-dimensional In Vitro Modeling of Stromal-Epithelial Interactions During Ovarian Cancer Initiation and Progression
Published on: August 28, 2012
Isolation and characterization of four alternate c-erbB3 transcripts expressed in ovarian carcinoma-derived cell
1Department of Biochemistry and Molecular Biology, Mayo Clinic, Rochester, Minnesota 55905, USA.
Abstract:
ErbB-3 is a member of the epidermal growth factor receptor (EGFR/ErbB) family. In addition to the previously reported 6.2 kb full-length and 1.4 kb truncated c-erbB3 transcripts, we have observed a 1.7 kb c-erbB3 human transcript in Northern blots that specifically hybridizes to a probe of the extracellular domain of the receptor. Using 3'-RACE we have isolated four novel c-erbB3 cDNA clones of 1.6, 1.7, 2.1 and 2.3 kb from a human ovarian carcinoma-derived cell line. All four alternate transcripts are synthesized by readthrough of an intron and use of an alternative polyadenylation signal within this intron. Identical c-erbB3 transcripts are expressed in normal human placental tissues. Expression of these alternate transcripts is tissue-specific as indicated by Northern blot and RNase protection analyses. Fibroblasts transfected with expression vectors carrying these alternate c-erbB3 cDNA clones stably express truncated ErbB-3 products. Three of these four cDNA clones express a receptor product that is secreted. Immunoprecipitation analysis of primary cultures of human ovarian carcinomas also demonstrate the expression of a 90 kDa ErbB-3 related protein that is secreted. Furthermore, we demonstrate conservation of the exon-intron junctions between members of the erbB gene family in those regions of the gene encoding the extracellular domain. This gene structure is also conserved in the c-erbB1 homologues of Drosophila and C. elegans. Growth regulatory roles for related truncated ErbB products recently have been reported. It is, therefore, possible that the products of these four alternate c-erbB3 transcripts may also play important growth regulatory roles in normal and transformed cells.
Insights
Researchers discovered novel, shorter human c-erbB3 transcripts in ovarian cancer cells and placental tissue. These alternate transcripts produce secreted ErbB-3 proteins, suggesting potential roles in cell growth regulation.
Area of Science:
- Molecular Biology
- Genetics
- Cancer Research
Background:
- The epidermal growth factor receptor (EGFR/ErbB) family includes ErbB-3.
- Previous studies identified 6.2 kb full-length and 1.4 kb truncated c-erbB3 transcripts.
Purpose of the Study:
- To investigate novel c-erbB3 transcripts and their protein products.
- To determine the expression patterns and potential functions of these transcripts.
Main Methods:
- Northern blot analysis
- 3'-RACE (Rapid Amplification of cDNA Ends)
- RNase protection assays
- Transfection of fibroblasts
- Immunoprecipitation
Main Results:
- A 1.7 kb c-erbB3 transcript was identified, along with four novel cDNA clones (1.6, 1.7, 2.1, 2.3 kb) arising from intron readthrough and alternative polyadenylation.
- These alternate transcripts are expressed in human ovarian carcinoma cell lines and normal placental tissues in a tissue-specific manner.
- Transfected cells stably expressed truncated ErbB-3 products, with three clones yielding secreted receptor proteins.
- A secreted 90 kDa ErbB-3 related protein was detected in primary human ovarian carcinomas.
- Exon-intron structure conservation was observed within the erbB gene family and with homologs in Drosophila and C. elegans.
Conclusions:
- Novel, alternate c-erbB3 transcripts generate secreted ErbB-3 protein products.
- These secreted proteins may play significant roles in the growth regulation of both normal and cancerous cells.
- The findings highlight the complexity of ErbB-3 expression and its potential implications in cancer biology.
More Related Videos
09:08Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020